文献速递消化道肿瘤与早癌消化内镜

在45岁而非50岁开始对平均风险人群进行结直肠癌筛查的成本效益与国家影响

Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years.
PubMed 文献 · Gastroenterology · 2019-03-28

美国癌症协会建议将结直肠癌筛查起始年龄从50岁提前至45岁。该研究采用经验证的马尔可夫模型比较筛查策略与替代资源分配,发现45岁起始结肠镜筛查具有成本效益,但将资源用于提高老年未筛查人群的参与率可获得更大获益且成本更低。

要点

  • 45岁起始结肠镜筛查每获得1个QALY需花费33,900美元,可避免4例结直肠癌和2例结直肠癌死亡。
  • 将同等758次结肠镜检查用于55岁或65岁未筛查人群至75岁,可避免13-14例结直肠癌和6-7例死亡并节省费用。
  • 提高50-75岁人群筛查率至80%可在三分之一增量成本下避免近3倍结直肠癌死亡。

核心结论

  • 马尔可夫模型分析发现,45岁起始结直肠癌筛查可能具有成本效益,但通过提高老年和高风险未筛查人群的参与率可获得更大获益且成本更低。

研究设计与样本

  • 采用经验证的马尔可夫模型比较筛查策略与替代资源分配,全国预测基于年龄别筛查参与率和人口普查数据。

主要发现

  • 在1000人中45岁而非50岁起始结肠镜筛查可避免4例结直肠癌和2例结直肠癌死亡,获得14个质量调整生命年(QALY),每获得1个QALY花费33,900美元,需额外758次结肠镜检查。
  • 同等758次结肠镜检查若用于55岁未筛查人群至75岁可避免13例结直肠癌和6例死亡,若用于65岁未筛查人群可避免14例结直肠癌和7例死亡,并节省163,700至445,800美元。
  • 提高粪便免疫化学检测异常后结肠镜完成率可获得更大获益和节省。
  • 45岁而非50岁起始粪便免疫化学检测每获得1个QALY花费7,700美元。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The American Cancer Society has recommended initiating colorectal cancer (CRC) screening at age 45 years instead of 50 years. We estimated the cost effectiveness and national effects of adopting this recommendation. METHODS: We compared screening strategies and alternative resource allocations in a validated Markov model. We based national projections on screening participation rates by age and census data. RESULTS: Screening colonoscopy initiation at age 45 years instead of 50 years in 1000 persons averted 4 CRCs and 2 CRC deaths, gained 14 quality-adjusted life-years (QALYs), cost $33,900/QALY gained, and required 758 additional colonoscopies. These 758 colonoscopies could instead be used to screen 231 currently unscreened 55-year-old persons or 342 currently unscreened 65-year-old persons, through age 75 years. These alternatives averted 13-14 CRC cases and 6-7 CRC deaths and gained 27-28 discounted QALYs while saving $163,700-$445,800. Improving colonoscopy completion rates after abnormal results from a fecal immunochemical test yielded greater benefits and savings. Initiation of fecal immunochemical testing at age 45 years instead of 50 years cost $7700/QALY gained. Shifting current age-specific screening rates to 5 years earlier could avert 29,400 CRC cases and 11,100 CRC deaths over the next 5 years but would require 10.7 million additional colonoscopies and cost an incremental $10.4 billion. Improving screening rates to 80% in persons who are 50-75 years old would avert nearly 3-fold more CRC deaths at one third the incremental cost. CONCLUSIONS: In a Markov model analysis, we found that starting CRC screening at age 45 years is likely to be cost effective. However, greater benefit, at lower cost, could be achieved by increasing participation rates for unscreened older and higher-risk persons.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Ladabaum U, Mannalithara A, Meester RGS, et al. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years. Gastroenterology. 2019. PMID: 30930021. doi:10.1053/j.gastro.2019.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。